These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22142151)

  • 1. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease.
    Postma MJ; Boersma C
    Expert Rev Clin Pharmacol; 2012 Jan; 5(1):1-4. PubMed ID: 22142151
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
    Mil'chakova AE; Popov GR; Bykov AV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):49-55. PubMed ID: 18567194
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: An economic Markov model evaluation.
    Kovacs N; Janszky J; Nagy F
    Drugs Aging; 2011 Feb; 28(2):161-2. PubMed ID: 21275441
    [No Abstract]   [Full Text] [Related]  

  • 7. The incorporation of potential confounding variables in Markov models.
    Nuijten MJ; Rutten F
    Pharmacoeconomics; 2003; 21(13):941-50. PubMed ID: 12959626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effect pharmacological studies of Parkinson's disease].
    Chikina ES; Belousov IuB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(11):68-72. PubMed ID: 16329642
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prevalence and main methods of treatment of advanced stages of Parkinson's disease].
    Seliverstov IuA; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):100-6. PubMed ID: 24479164
    [No Abstract]   [Full Text] [Related]  

  • 10. Systematic review of the pharmacoeconomics of Parkinson disease medications.
    Wang AS; Gunzler SA
    Expert Opin Pharmacother; 2019 Sep; 20(13):1659-1670. PubMed ID: 31150294
    [No Abstract]   [Full Text] [Related]  

  • 11. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
    Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
    Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
    Noyes K; Dick AW; Holloway RG;
    Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of unilateral and bilateral pallidotomy for Parkinson's disease.
    Green AL; Joint C; Sethi H; Bain P; Aziz TZ
    J Clin Neurosci; 2004 Nov; 11(8):829-34. PubMed ID: 15519857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of patients with early Parkinson's disease.
    Rascol O; Brefel-Courbon C; Payoux P; Ferreira J
    Adv Neurol; 2003; 91():203-11. PubMed ID: 12442679
    [No Abstract]   [Full Text] [Related]  

  • 15. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
    Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
    Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic evaluation of pharmacotherapies for Parkinson's disease.
    Coyle D; Barbeau M; Guttman M; Baladi JF
    Parkinsonism Relat Disord; 2003 Jun; 9(5):301-7. PubMed ID: 12781598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entacapone: adjunctive use in patients with advanced Parkinson's disease.
    McAuley L
    Issues Emerg Health Technol; 2000 Dec; (12):1-7. PubMed ID: 11902220
    [No Abstract]   [Full Text] [Related]  

  • 19. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of uncertainty in health economic modelling studies.
    O'Hagan A; McCabe C; Akehurst R; Brennan A; Briggs A; Claxton K; Fenwick E; Fryback D; Sculpher M; Spiegelhalter D; Willan A
    Pharmacoeconomics; 2005; 23(6):529-36. PubMed ID: 15960550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.